Form 4: Enliven Therapeutics CFO Benjamin Hohl Exercises Options and Sells Shares
SEC Form 4
Enliven Therapeutics' CFO, Benjamin Hohl, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 28, 2024, Benjamin Hohl, the CFO of Enliven Therapeutics, exercised stock options to acquire 4,250 shares of common stock at a price of $2.48 per share.
- Simultaneously, Hohl sold 1,906 shares at a weighted average price of $22.89, 2,334 shares at a weighted average price of $23.4184, and 10 shares at $24.34.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
- Following these transactions, Hohl directly owns 2,344 shares of common stock and holds options for 216,870 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports routine transactions under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It is common for executives to exercise stock options and sell shares, often under pre-arranged trading plans like Rule 10b5-1, to manage personal finances.
Key Dates
| Date | Description |
|---|---|
| June 26, 2023 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| August 2, 2022 | Date when one-fourth of the stock options vested. |
| May 28, 2024 | Date of the stock option exercise and share sales. |
| May 30, 2024 | Date of signature on the Form 4 filing. |
| August 02, 2031 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.